SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : PHARMERICA (DOSE) - Undervalued Growth Company
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Rob Anderson who wrote (11)11/5/1998 1:24:00 PM
From: Joe Dancy  Read Replies (1) of 24
 
For what it is worth: DOSE: BUCKINGHAM RES reconfirms the recommendation as Strong Buy on 11/04/98

I like the company. The thing that concerns me is that like Columbia/HCA that went on an acquisition tear only to fall apart in the hospital business and have the execs indicted for billing problems, it is difficult for DOSE or anyone else to integrate purchased entities and staff into a coherant well managed ongoing concern.

At the current price, I think this concern is priced into the market, as well as other fears with regard to earnings. Good to see analysts stay on board.

Best - Joe
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News